secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2025-07-16T23:59:59+00:00
Accession:  0001213900-25-064467
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharmaceuticals regains Nasdaq compliance with stockholders' equity requirement after $3.6M offering
--------------------------------------------------------------------------------

- Nasdaq confirmed compliance with Listing Rule 5550(b)(1) as of July 14, 2025.
- Deficiency arose from $2.13M equity as of Mar 31, 2025, below $2.5M minimum.
- June 2025 best-efforts offering raised ~$3.6M gross via shares and warrants.
- Nasdaq will monitor ongoing compliance; next periodic report may trigger re-evaluation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390025064467/0001213900-25-064467-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390025064467/ea0249089-8k_adial.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-064467

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer